SY
Symbiotec Pharmalab Ltd (SYMBIOTEC)
₹1,598.60
Mkt cap
₹10,354 Cr
P/E ratio
70.00
P/B
7.54
Div yield
0.00%
ROE
11.70%
ROCE
13.00%
EPS (TTM)
₹22.84
Book value
₹212
52W range
934–1,665
Sector
Healthcare
Price history
Previous close
Symbiotec is a research-driven, science- based pharmaceutical and biotechnology company with a strong global leadership position in Corticosteroid and Steroidal Hormone Active Pharmaceutical Ingredients (APIs). It has evolved from a Lab-Scale Steroid manufacturer into a fully integrated global platform. [1]
NSE SYMBIOTECBSE 544889
Health check
Cautious
ValuationExpensive
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−3.98% from high₹1,599
₹934+71.12% from low₹1,665
Current
₹1,598.60
Prev close
₹1,604.80
Day
−0.39%
Price performance
1D
+0.06%
1W
−0.34%
1M
+34.10%
3M
—
6M
—
1Y
—
YTD
+45.63%
Financials
Revenue, profit & margin
P/E ratio
70.0×
SYMBIOTEC is 106% above the sector median of 34.0×
SYMBIOTEC70.0×
Sector median34.0×
| Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|
| Sales | 203 | 196 | 245 | 218 | 280 | |
| YoY Sales growth | +7% | +43% | ||||
| Expenses | 145 | 145 | 183 | 173 | 188 | |
| Operating Profit | 58 | 50 | 62 | 45 | 92 | |
| OPM % | 29% | 26% | 25% | 21% | 33% | |
| Other Income | 3 | 0 | 0 | 0 | 0 | |
| Interest | 5 | 6 | 7 | 6 | 6 | |
| Depreciation | 11 | 11 | 20 | 22 | 22 | |
| Profit before tax | 45 | 33 | 35 | 18 | 64 | |
| Tax % | 33% | 43% | 22% | 20% | 19% | |
| Net Profit | 30 | 19 | 28 | 14 | 52 | |
| EPS in Rs | 46.99 | 30.18 | 4.39 | 2.24 | 8.05 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202633.28%Promoter
Promoters33.28%
FIIs3.79%
DIIs33.17%
Public29.77%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,880.00 | 36.66 | 4,51,075 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,442.00 | 88.89 | 3,03,749 | 0.26% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,670.00 | 81.82 | 1,77,632 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,424.00 | 97.75 | 1,30,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,189.90 | 26.20 | 1,18,693 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,380.00 | 41.17 | 1,15,267 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,391.80 | 36.21 | 1,12,442 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Symbiotec Pharma | ₹1,611.30 | 70.04 | 10,354 | 0.00% | 52 | +169.15% | 280 | +43.17% | 12.99% |
| Median: 160 Co. | ₹465.83 | 33.99 | 2,012 | 0.08% | 13 | +33.53% | 179 | +20.92% | 14.94% |
Filings
Annual reports1
Concall transcripts7
Credit ratings1
Announcements5
Announcement under Regulation 30 (LODR)-Earnings Call Transcript 12 Nov - Transcript of the Earnings conference call for the Analysts and Investors for the Quarter and Half year endedAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 12 Nov - Symbiotec will attend Avendus Spark investor conference on 16 November 2026 in Mumbai.Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Nov - The News Paper advertisement with respect to the unaudited Financial Results of the company for the quarter and half year ended September 30, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 6 Nov - Audio recording of analysts’ and investors’ conference call held on November 06, 2026, posted online.Announcement Under Regulation 30 (LODR)-Updates (Symbiotec Signs 10-Year Take-Or-Pay Agreement To Manufacture Fermentation-Based Alternative Protein For EU Innovator) 6 Nov - Signed 10-year take-or-pay CDMO deal to manufacture fermentation-based alternative protein for a European innovator.






